AURKA and T-cell non-Hodgkin lymphoma: A phase 2 study for MLN8237 (alisertib), a selective Aurora-A kinase inhibitor, found an overall response rate of 27% in patients with relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas (27).